HLB Genex, Inc. Logo

HLB Genex, Inc.

Develops and produces customized enzyme and microbiome-based solutions.

187420 | KO

Overview

Corporate Details

ISIN(s):
KR7187420005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노1로 65(관평동), 대전광역시

Description

HLB Genex, Inc. is a biotechnology company that develops and produces customized enzyme and microbiome-based solutions. The company's core activities involve the research, development, and manufacturing of industrial special enzymes and bio-healthcare ingredients. Its key products include enzymes like Lactase for food applications, Catalase for eco-friendly industrial processes, and Proteinase K for molecular diagnostics. In the bio-healthcare segment, it produces Vitamin K2 (Menaquinone 7) for bone and cardiovascular health and Phytosphingosine for cosmeceuticals. The company utilizes proprietary platform technologies, such as Microbial Surface Display and Spore Biologics, to develop its products and advance its pipeline of microbiome therapeutics by identifying effector molecules, also known as postbiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-23 00:00
사업보고서 (2022.12)
Korean 1.6 MB
2023-03-16 00:00
주주총회소집결의
Korean 13.6 KB
2023-03-16 00:00
주주총회집중일개최사유신고
Korean 4.5 KB
2023-03-16 00:00
주주총회소집공고
Korean 207.0 KB
2023-02-22 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.3 KB
2023-01-09 00:00
풍문또는보도에대한해명(최종답변)
Korean 5.4 KB
2022-12-29 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.9 KB
2022-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2022-12-13 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 156.5 KB
2022-12-13 00:00
주식등의대량보유상황보고서(일반)
Korean 159.7 KB
2022-11-30 00:00
주식등의대량보유상황보고서(약식)
Korean 60.2 KB
2022-11-24 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.2 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.4 MB
2022-10-07 00:00
풍문또는보도에대한해명(미확정)
Korean 5.4 KB
2022-09-08 00:00
풍문또는보도에대한해명(미확정)
Korean 4.9 KB

Automate Your Workflow. Get a real-time feed of all HLB Genex, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Genex, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Genex, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alzinova AB Logo
Clinical-stage biopharma developing immunotherapies for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops and commercializes therapeutics to improve cardiovascular health.
United States of America
AMRN
AMGEN INC Logo
A biotechnology company developing human therapeutics for serious illnesses.
United States of America
AMGN
Industrial biotechnology company specializing in specialty enzymes and proteins.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Biotechnology company developing therapies for rare genetic and devastating diseases.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Specialty manufacturer of high-purity chiral amino acids and their derivatives.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops, manufactures, and distributes generic and specialty pharmaceuticals.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops, manufactures, and markets technically challenging medications.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Develops therapies for neurodegenerative diseases and other unmet medical needs.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Biopharmaceutical firm developing boron-based drugs for infectious diseases.
United States of America
ANTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.